People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cleveland Diagnostics, Inc. | — | Biotechnology | Series C | $73.3M | $79.4M | 2024 |
| CytoTronics, Inc. | — | Other Technology | Series A | $13.5M | $83.1M | 2024 |
SAMEER ROHATGI at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside SAMEER ROHATGI on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ben Bronstein | 1 | 4 |
| Jeffrey Marshall | 1 | 3 |
| Karen Shanahan | 1 | 3 |
| ANDREW SUMMERS | 1 | 3 |
| Jenna Abelli | 1 | 2 |
| Arnon Chait | 1 | 2 |
| NOEL JEE | 1 | 2 |
| JOSEPH RICH | 1 | 2 |
| Levi Kushnir | 1 | 1 |
| DARA WRIGHT | 1 | 1 |
| Tim Longville | 1 | 1 |
| Jeffrey Abbott | 1 | 1 |
| Douglas Kahn | 1 | 1 |
| Wenxuan Wu | 1 | 1 |
| Ilan Goldstein | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.